D07.2
Carcinoma in situ of vagina
Clinical Classification Guidelines
Inclusion Terms
- Severe dysplasia of vagina
- Vaginal intraepithelial neoplasia III [VAIN III]
Excludes Type 1
- moderate dysplasia of vagina (N89.1)
- vaginal intraepithelial neoplasia II [VIN II] (N89.1)
Medical Intelligence & Overview
Carcinoma in situ of the vagina, also known as vaginal intraepithelial neoplasia III (VAIN III), is a precursor to invasive vaginal cancer. It involves abnormal cell growth confined to the surface layer of the vaginal lining, without invasion into underlying tissues. Recognized as a severe form of dysplasia, this condition necessitates careful diagnosis and management to prevent progression to malignancy.
Causes & Symptoms
Clinical Causes: Persistent infection with high-risk human papillomavirus (HPV) types, especially HPV 16 and 18 History of cervical or other genital intraepithelial neoplasia Immunosuppression, such as from HIV/AIDS or organ transplantation Genetic predispositions that affect cellular control mechanisms Smoking, which can impair immune response and promote cellular mutations Multiple sexual partners or early sexual activity, increasing HPV exposure
Key Symptoms: Often asymptomatic, especially in early stages Vaginal bleeding, particularly after sexual intercourse Vaginal discharge that may be abnormal or foul-smelling Discomfort or pain during intercourse A visible or palpable lesion or abnormal pigmentation on vaginal examination Persistent itching or irritation in the vaginal area
Diagnostic & Treatment
Diagnosis Path: Vaginal biopsy to examine tissue under a microscope for abnormal cell growth Pap smear tests, although less definitive for vaginal lesions compared to cervical screening Colposcopy, a detailed examination of the vaginal walls with magnification and application of acetic acid or Lugol's iodine to highlight abnormal areas HPV testing to identify the presence of high-risk HPV types
Treatment Protocols: Topical therapies such as imiquimod cream to boost local immune response and promote clearance of abnormal cells Laser therapy to destroy precancerous tissue with minimal damage to surrounding areas Surgical excision to remove localized lesions when accessible Vaginal laser ablation or electrocautery as minimally invasive options Follow-up surveillance with regular examinations and testing to monitor for recurrence or progression
Clinical Advice & FAQs
Billing Guidance
Is D07.2 a billable ICD-10 code?
Yes, D07.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D07.2?
Clinical documentation must specify the nature of Carcinoma in situ of vagina and any associated comorbidities for accurate reporting.
Cite this Clinical Reference